These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28749571)

  • 1. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Sidhu SS; Sharma BC; Goyal O; Kishore H; Kaur N
    Hepatology; 2018 Feb; 67(2):700-710. PubMed ID: 28749571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
    Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A
    Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
    Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
    He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
    Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
    Butterworth RF
    Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
    Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
    Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
    Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
    J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.
    Alvares-da-Silva MR; de Araujo A; Vicenzi JR; da Silva GV; Oliveira FB; Schacher F; Oliboni L; Magnus A; Kruel LP; Prieb R; Fernandes LN
    Hepatol Res; 2014 Sep; 44(9):956-63. PubMed ID: 24033861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
    Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
    Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.